Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Blood Advances|April 10, 2019
Targeting CD47 in Sézary syndrome with SIRPαFcLisa D S Johnson, Swati Banerjee, Oleg Kruglov, et al.
Research Square|January 30, 2023
Necroptosis Drives Major Adverse Cardiovascular Events During Severe COVID-19Rosana Wiscovitch-Russo, Elsa D Ibáñez-Prada, Cristian C Serrano-Mayorga, et al.
Critical Care (London, England)|April 20, 2023
Major adverse cardiovascular events are associated with necroptosis during severe COVID-19Rosana Wiscovitch-Russo, Elsa D Ibáñez-Prada, Cristian C Serrano-Mayorga, et al.
NPJ Vaccines|July 1, 2026
COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2Grace E West, Rebecca B Morse, Benjamin L Sievers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseE L Sievers, R A Larson, E A Stadtmauer, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Science Translational Medicine|January 7, 2021
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomideMax Jan, Irene Scarfò, Rebecca C Larson, et al.
Blood|May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogsAdam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Pageof 14